SetPoint System
SetPoint Medical · Decision date Feb 18, 2026
What did the FDA approve?
FDA records P240039/S002 as a supplement to PMA P240039, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Feb 18, 2026.
FDA approval order statement
The firm requested approval to implement two supplier changes to the implant component of the SetPoint System for the printed circuit board assembly and the battery. Based upon the information submitted, the PMA supplement is approved.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Feb 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240039/S002
- Regulatory pathway
- PMA supplement
- Applicant
- SetPoint Medical
- Product code
- SFJ
- Decision code
- APPR
- Decision date
- Feb 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Vagus nerve stimulator for rheumatoid arthritis.
- Applicant
- SetPoint Medical
- Product code
- SFJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240039. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240039 · Original PMA
SetPoint System
P240039/S002 received
Application receipt date recorded by FDA.
P240039/S001 · Related supplement
SetPoint System
P240039/S002 · FDA decision
135 Review Track For 30-Day Notice
P240039/S003 · Related supplement
Charger SetPoint System
P240039/S004 · Related supplement
SetPoint System
Timeline entries are records held by MedtechLedger for P240039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SetPoint SystemP240039 | SetPoint Medical | PMA approval | Jul 30, 2025 | FDA |
SetPoint SystemP240039/S001 | SetPoint Medical | PMA supplement | Jan 16, 2026 | FDA |
Charger SetPoint SystemP240039/S003 | SetPoint Medical | PMA supplement | Oct 16, 2026 | FDA |
SetPoint SystemP240039/S004 | SetPoint Medical | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
SetPoint Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 25101 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P240039/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

